Pulmonary Arterial Hypertension Caused by Treatment with Dasatinib for Chronic Myeloid Leukemia -Critical Alert-

Makoto Sano; Masao Saotome; Tsuyoshi Urushida; Hideki Katoh; Hiroshi Satoh; Kazunori Ohnishi; Hideharu Hayashi

doi:10.2169/internalmedicine.51.7472

CASE REPORTS

Pulmonary Arterial Hypertension Caused by Treatment with Dasatinib for Chronic Myeloid Leukemia -Critical Alert-

Makoto Sano, Masao Saotome, Tsuyoshi Urushida, Hideki Katoh, Hiroshi Satoh, Kazunori Ohnishi, Hideharu Hayashi

Author information

Keywords: dasatinib, pulmonary arterial hypertension, chronic myeloid leukemia

JOURNAL OPEN ACCESS

2012 Volume 51 Issue 17 Pages 2337-2340

DOI https://doi.org/10.2169/internalmedicine.51.7472

Details

Abstract

We present a case of pulmonary arterial hypertension (PAH), which is potentially related to treatment with dasatinib (Sprycel^®). A 61-year-old woman, who had been treated with dasatinib for 27 months for chronic myeloid leukemia (CML), visited our hospital complaining of dyspnea. In right heart catheterization, her mean pulmonary arterial pressure was 35 mmHg. After other possible etiologies to cause PAH were excluded, the patient was diagnosed as a dasatinib-related PAH. As notified by U.S. Food and Drug Administration (FDA) in October 2011, we recommend routine cardiopulmonary evaluation before and during treatment with dasatinib in CML patients in terms of the adverse effects of PAH.

Corresponding author

Register with J-STAGE for free!